Europe Blister Packaging Market Size

Europe Blister Packaging Market Analysis

The Europe Blister Packaging Market is expected to reach a CAGR of 6.45% during the forecast period of 2021-2026. The outbreak of COVID-19, growth in regulatory norms across the world, population health management, inventions, more informed customers, and an increase in OTC drugs have augmented the growth of packaging.

• Growing pressure on pharmaceutical companies to manufacture medicines that are different in packaging and hard to imitate, surpassing the basic need of keeping it useful for the purpose it was produced, for it to be made available for patients, due to growth in diseases and stringent government regulations against counterfeit drugs, are among the significant factors propelling the market. Blister packaging provides an efficient method of anti-counterfeit systems, like banknote authentication systems and others.
• The UK pharmaceutical industry is one of the major players in the research and innovation of the country. The industry contributes billions on R&D and employs vast numbers for highly-skilled R&D roles. According to the Association of the British Pharmaceutical Industry (ABPI), 23,000 people work in R&D out of 73,000 people employed directly by the pharmaceutical industry.
• The massive investments and the proportion of skilled workers employed show how Britain is building up the pipeline of medicines and future drugs. These ongoing investments are expected to provide an excellent opportunity for the growth of blister packaging in the country.
• The use of innovative technologies in blisters, such as RFID (radio frequency identification tags), deployed with a seal applied outside the packaging, is increasing due to the potential to offer individual security throughout supply chains. Contamination of samples in blisters only occurs when a single capsule or tablet is dispensed or administered when the protective barrier is broken.
• Furthermore, the outbreak has increased the research across the world for developing a vaccine for COVID-19. For instance, the healthcare giant, Johnson & Johnson, started clinical trials in September 2020 and has received a nearly USD 500 million partnership via a US Department of Health and Human Services division.
• Also, experimental vaccines developed by researchers at the University of Pittsburgh and Baylor College of Medicine in Houston are also waiting for permission from the Food and Drug Administration to begin testing in people. The success of these vaccines developed by the researchers might follow the large-scale manufacture of them, further driving the demand for liquid bottles.